This study establishes a machine learning-optimized 3-gene prognostic signature (EGR3, RECQL4, MMP1) that bridges prognostic stratification and tumor-immune interplay in breast cancer, offering both clinical and mechanistic advancements. This evidence concerns the gene EGR3 and breast carcinoma.